Premium Phosphosite-Specific 7TM Antibodies
Your Resource for GPCR Research
Select Your Country of Delivery below

Gastric Inhibitory Polypeptide Receptor Antibodies

Close filters
No results were found for the filter!
NEW
Validation of the Gastric Inhibitory Polypeptide Receptor in transfected HEK293 cells
GIPR (non-phospho) Gastric Inhibitory...
The non-phospho GIPR antibody is directed against the distal end of the carboxyl-terminal tail human GIPR. It can be used to detect total GIPR receptors in Western blots independent of phosphorylation. It can also be used to isolate and...
$ 375.00 *
Details
NEW
Agonist-induced Threonine442/Serine443 phosphorylation of GIPR.
pT442/pS443-GIPR (phospho-Gastric Inhibitory...
Threonine442/Serine443 (T442/S443) is major phosphorylation site of human GIP receptor. The pT442/pS443-GIPR antibody detects phosphorylation in response to agonists. T442/S443 phosphorylation is likely to be involved in efficient ligand...
$ 375.00 *
Details
NEW
Agonist-induced Serine433/Serine435 phosphorylation of GIPR
pS433/pS435-GIPR (phospho-Gastric Inhibitory...
Serine433/Serine435 (S433/S435) is major phosphorylation site of human GIP receptor. The pS433/pS435-GIPR antibody detects phosphorylation in response to agonists. S433/S435 phosphorylation is likely to be involved in efficient ligand...
$ 375.00 *
Details

The glucose-dependent insulinotropic polypeptide receptor (GIPR), encoded by GIPR, is a class B1 G protein-coupled receptor activated by GIP, an incretin hormone released from intestinal K cells after nutrient ingestion. It couples predominantly to Gs, stimulating adenylyl cyclase and increasing intracellular cAMP. GIPR is expressed on pancreatic β-cells, where it enhances glucose-dependent insulin secretion. It is also expressed in pancreatic α-cells, adipose tissue, and selected brain regions, linking GIP signaling to glucagon secretion, nutrient storage, and energy balance. The insulinotropic response to GIP is impaired in many patients with type 2 diabetes, although it can improve with better glycemic control. Agonist stimulation can induce β-arrestin recruitment and receptor internalization, with trafficking and desensitization differing between human and rodent receptors. Tirzepatide, a dual GIP/GLP-1 receptor agonist, is approved for type 2 diabetes and chronic weight management. Maridebart cafraglutide, which combines GIPR antagonism with GLP-1 receptor agonism, has entered clinical development for obesity. GIP receptor desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal serine433/serine435 (pS433/pS435-GIPR) and threonine442/serine443 (pT442/pS443-GIPR). This nomenclature refers to the human GIPR. For more information on GIPR pharmacology please refer to the IUPHAR database. For further reading refer to:

Mayo KE, Miller LJ, Bataille D, Dalle S, Göke B, Thorens B, Drucker DJ. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev. 2003 Mar;55(1):167-94. doi: 10.1124/pr.55.1.6. PMID: 12615957.

Bataille D, Chan SL, Delagrange P, Drucker DJ, Göke B, Hills R, Mayo KE, Miller LJ, Salvatori R, Thorens B. Glucagon receptor family in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1).

The glucose-dependent insulinotropic polypeptide receptor (GIPR), encoded by GIPR , is a class B1 G protein-coupled receptor activated by GIP, an incretin hormone released from intestinal K... read more »
Close window
Gastric Inhibitory Polypeptide Receptor Antibodies

The glucose-dependent insulinotropic polypeptide receptor (GIPR), encoded by GIPR, is a class B1 G protein-coupled receptor activated by GIP, an incretin hormone released from intestinal K cells after nutrient ingestion. It couples predominantly to Gs, stimulating adenylyl cyclase and increasing intracellular cAMP. GIPR is expressed on pancreatic β-cells, where it enhances glucose-dependent insulin secretion. It is also expressed in pancreatic α-cells, adipose tissue, and selected brain regions, linking GIP signaling to glucagon secretion, nutrient storage, and energy balance. The insulinotropic response to GIP is impaired in many patients with type 2 diabetes, although it can improve with better glycemic control. Agonist stimulation can induce β-arrestin recruitment and receptor internalization, with trafficking and desensitization differing between human and rodent receptors. Tirzepatide, a dual GIP/GLP-1 receptor agonist, is approved for type 2 diabetes and chronic weight management. Maridebart cafraglutide, which combines GIPR antagonism with GLP-1 receptor agonism, has entered clinical development for obesity. GIP receptor desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal serine433/serine435 (pS433/pS435-GIPR) and threonine442/serine443 (pT442/pS443-GIPR). This nomenclature refers to the human GIPR. For more information on GIPR pharmacology please refer to the IUPHAR database. For further reading refer to:

Mayo KE, Miller LJ, Bataille D, Dalle S, Göke B, Thorens B, Drucker DJ. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev. 2003 Mar;55(1):167-94. doi: 10.1124/pr.55.1.6. PMID: 12615957.

Bataille D, Chan SL, Delagrange P, Drucker DJ, Göke B, Hills R, Mayo KE, Miller LJ, Salvatori R, Thorens B. Glucagon receptor family in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1).

Recently viewed